Topical Calcineurin Inhibitor Site Selection
Use pimecrolimus 1% cream for mild-to-moderate atopic dermatitis on sensitive skin areas (face, neck, genitals, body folds), and use tacrolimus 0.03% or 0.1% ointment for any skin area when treating moderate-to-severe atopic dermatitis or when more potent therapy is needed. 1
Primary Recommendations by Disease Severity
Pimecrolimus 1% Cream
- Indicated for: Mild-to-moderate AD 1
- Preferred locations: Face, neck, genitals, and body folds where topical corticosteroid adverse effects (atrophy, telangiectasia, striae) are most concerning 2
- Application: Twice daily to affected areas only 3
- Applied as a thin layer; stop when symptoms resolve 3
Tacrolimus Ointment (0.03% or 0.1%)
- Indicated for: Moderate-to-severe AD 1
- Can be used on: All skin regions including face, neck, and body folds 1
- Formulation selection:
- 0.03% for ages 2-15 years
- 0.1% for ages ≥16 years 2
Key Clinical Decision Points
When choosing between the two agents:
Disease severity drives the choice: Tacrolimus has stronger evidence for moderate-to-severe disease, while pimecrolimus is specifically recommended for mild-to-moderate disease 1
Sensitive skin areas favor pimecrolimus: While both can be used on thin skin, pimecrolimus has been specifically studied and shown effective on sensitive areas without causing the epidermal thinning seen with even mild-potency topical corticosteroids 4
Tacrolimus 0.03% and pimecrolimus show similar efficacy: When comparing tacrolimus 0.03% to pimecrolimus 1%, no significant differences in efficacy or safety were observed 4
Important Caveats
- Do not use under occlusive dressings with either agent 3
- Limit application to areas of active AD involvement 3
- Avoid continuous long-term use; apply only during flares and discontinue when symptoms resolve 3
- Re-evaluate if symptoms persist beyond 6 weeks to confirm AD diagnosis 3
Safety Considerations
Both agents carry an FDA black box warning regarding theoretical cancer risk, but moderate-certainty evidence from 3.4 million patients shows topical calcineurin inhibitors do not increase cancer risk (OR 1.03,95% CI 0.94-1.11) 5. The absolute cancer risk with topical calcineurin inhibitors (4.70 per 1000) was not different from controls (4.56 per 1000) 5.